Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144586 | 0.99 | MAOA (1.00) | MAOAMAOB | |
| SCHEMBL17150990 | 0.97 | MAOA (1.00) | MAOAMAOB | |
| SCHEMBL17150982 | 0.84 | MAOA (0.74) | MAOAMAOB | |
| SCHEMBL17144584 | 0.82 | MAOA (1.00) | MAOAMAOB | |
| SCHEMBL17150981 | 0.82 | MAOA (0.76) | MAOAMAOB | |
| SCHEMBL18998987 | 0.81 | MAOA (1.00) | MAOAMAOB | |
| Hydrochloric Acid SCHEMBL18980612 | 0.81 | MAOA (0.97) | MAOAMAOB | |
| SCHEMBL28695989 | 0.81 | MAOB (1.00) | MAOAMAOB | |
| SCHEMBL19017688 | 0.80 | MAOA (1.00) | MAOAMAOB | |
| SCHEMBL17150988 | 0.80 | MAOA (0.68) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117159541-B | Application of NAT10 antagonist in preparation of medicines for preventing and/or treating epilepsy | University of South China (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117731781-A | Application of NAT10 promoter in preparation of synergist for enhancing liver cancer immunotherapy effect | 浙江大学 | 2024-03-22 | — | — | CN | disclosed |
| CN-115844885-B | Application of nat10 small molecule inhibitor in preparation of medicine for treating cerebral arterial thrombosis | 徐州医科大学 | 2024-02-06 | — | — | CN | disclosed |
| CN-117159541-A | Application of NAT10 antagonist in preparation of medicines for preventing and/or treating epilepsy | 南华大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| EP-3675880-B1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | UNIV JOHNS HOPKINS (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-115844885-A | Application of nat10 small molecule inhibitor in preparation of medicine for treating cerebral arterial thrombosis | 徐州医科大学 | 2023-03-28 | — | — | CN | disclosed |
| US-20220265609-A1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | UNIV JOHNS HOPKINS (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2019046791-A9 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-07-07 | — | — | WO | disclosed |
| US-11273148-B2 | Targeted epigenetic therapy for inherited aortic aneurysm condition | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273148-B2 | Targeted epigenetic therapy for inherited aortic aneurysm condition | HDAC1, HDAC11, HDAC7 | MAOA 4249/4885MAOB 4151/4885 |
| US-20220265609-A1 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION | HDAC1, HDAC11, HDAC7 | MAOA 4249/4885MAOB 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.